Vivos Therapeutics Operating Income Over Time
| VVOS Stock | USD 1.40 0.01 0.71% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vivos Therapeutics Performance and Vivos Therapeutics Correlation. Is there potential for Health Care Equipment & Supplies market expansion? Will Vivos introduce new products? Factors like these will boost the valuation of Vivos Therapeutics. If investors know Vivos will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Vivos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share | Quarterly Revenue Growth 0.757 | Return On Assets | Return On Equity |
Investors evaluate Vivos Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Vivos Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Vivos Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Vivos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vivos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Vivos Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Vivos Therapeutics and related stocks such as Allurion Technologies, enVVeno Medical Corp, and Co Diagnostics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALUR | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (5.2 K) | (12.5 M) | (32 M) | (79.1 M) | (50.2 M) | (45.2 M) | (47.4 M) |
| NVNO | (952.7 K) | (952.7 K) | (952.7 K) | (952.7 K) | (952.7 K) | (1.3 M) | (4.7 M) | (6.1 M) | (7.9 M) | (7.7 M) | (9.1 M) | (16.9 M) | (24.9 M) | (25.2 M) | (23.8 M) | (21.4 M) | (20.4 M) |
| CODX | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (2 M) | (1.7 M) | (4.6 M) | (6.1 M) | (5.9 M) | 41.7 M | 46.1 M | (27 M) | (42.7 M) | (40.1 M) | (36.1 M) | (34.3 M) |
| AEMD | (1.5 K) | (3.1 M) | (3.6 M) | (3.1 M) | (4 M) | (4.4 M) | (6.1 M) | (4.8 M) | (6 M) | (5.9 M) | (7.9 M) | (10.4 M) | (11.9 M) | (12.6 M) | (9.3 M) | (8.4 M) | (8 M) |
| COCH | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (701) | (6.9 M) | (8.7 M) | (18.4 M) | (19.3 M) | (17.3 M) | (16.5 M) |
| ADGM | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (13.5 K) | (20.6 M) | (23.9 M) | (27.9 M) | (62.5 M) | (56.2 M) | (53.4 M) |
| OSRH | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (3.3 K) | (35.4 K) | (1.8 M) | (3.5 M) | (3.2 M) | (3 M) |
| ANL | (19.1 M) | (19.1 M) | (19.1 M) | (19.1 M) | (19.1 M) | (19.1 M) | (19.1 M) | (19.1 M) | (19.1 M) | (19.1 M) | (26.1 M) | (8.6 M) | (67.3 M) | (67.6 M) | (54.9 M) | (49.4 M) | (51.9 M) |
| LPCN | (5.2 K) | (5.2 K) | (76.7 K) | (8.8 M) | (20.5 M) | (18.4 M) | (18.5 M) | (21.2 M) | (11.3 M) | (12.9 M) | (18 M) | 3.1 M | (12.1 M) | (17.9 M) | (1.2 M) | (1 M) | (1.1 M) |
| AMS | 400 K | 1.6 M | 730 K | 1.1 M | (50 K) | 2 M | 3.3 M | 2.4 M | 1.9 M | (4.5 M) | (9.5 M) | 1.4 M | 2.4 M | 270 K | (2.8 M) | (2.5 M) | (2.4 M) |
Vivos Therapeutics and related stocks such as Allurion Technologies, enVVeno Medical Corp, and Co Diagnostics Operating Income description
Operating Income is the amount of profit realized from Vivos Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Vivos Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Vivos Therapeutics | VVOS |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 7921 Southpark Plaza, |
| Exchange | NASDAQ Exchange |
USD 1.4
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.